Innovative Medicines based on
IMBiologics is a biotechnology company established in August 2020 with the slogan ‘Innovative Medicines based on ImmunoModulatory Biologics'.
Our goal is to invent novel treatment options for autoimmune diseases and cancer, utilizing antibodies to modulate the immune system through innovative mechanisms of action. We have initiated the journey with a 4 Billion KRW seed fund in 2020 to enable the development of proprietary antibody platform technology as well as the in-house R&D of in-licensed novel antibody assets. IMB successfully raised 13 Billion KRW in Series A financing in August 2021, and we are fully committed to accelerating the antibody R&D processes. We are establishing a clinical development team to efficiently bring our antibody pipelines into the clinic and collaborating with CDMO for GMP manufacturing.
Aiming to be listed on KOSDAQ in 2025, our final goal is to become a global leading biotech company by joining forces with global pharmaceutical companies by 2030.
Our vision is to develop Innovative Medicines based on ImmunoModulatory Biologics in areas of greatest unmet medical needs to become a global biotechnology company that benefits the world.